Metellus

Metellus AG operates as a private investment office, actively guiding deep technology and biotechnology companies from start-up to IPO. Specializing in disruptive innovations, their deep tech focus includes critical wireless systems and foundational semiconductor technologies for AI applications. Biotech targets novel immune modulation approaches, restoring immune balance for chronic conditions.

Established in 2008 by Michael Albisser, Metellus AG was founded on the insight that hands-on guidance accelerates high-potential ventures. Albisser and his team serve as principal investors, leveraging experience to shape strategy and fortify leadership, integrating expertise beyond capital provision. This active ownership model allows for close collaboration and strategic direction within their portfolio.

Metellus AG partners with pioneering deep tech and biotech firms developing next-generation applications and therapeutic breakthroughs. Their vision fosters innovations addressing global challenges, from advanced AI capabilities to curative solutions for chronic diseases. Through rigorous validation and talent sourcing, Metellus AG seeks substantial market impact and global deployment of disruptive technologies.